{"id":22029,"date":"2023-01-27T08:00:00","date_gmt":"2023-01-27T08:00:00","guid":{"rendered":"https:\/\/d36deud6t4mnhi.cloudfront.net\/press-releases\/ipsen-recoit-un-avis-negatif-du-chmp-sur-lemploi-du-palovarotene-pour-traiter-les-personnes-atteintes-de-fibrodysplasie-ossifiante-progressive-vivant-dans-lunion-europeenne\/"},"modified":"2024-07-22T11:11:28","modified_gmt":"2024-07-22T09:11:28","slug":"ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u","status":"publish","type":"press_release","link":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/","title":{"rendered":"Ipsen re\u00e7oit un avis n\u00e9gatif du CHMP sur l\u2019emploi du palovarot\u00e8ne pour traiter les personnes atteintes de fibrodysplasie ossifiante progressive vivant dans l\u2019Union europ\u00e9enne."},"content":{"rendered":"\n

PARIS (France), le 27 <\/strong>Janvier<\/strong> 2023 <\/strong>\u2014 Ipsen (Euronext : IPN ; ADR : IPSEY) a annonc\u00e9 aujourd\u2019hui que le comit\u00e9 des m\u00e9dicaments \u00e0 usage humain (CHMP) de l\u2019Agence europ\u00e9enne du m\u00e9dicament (AEM) a recommand\u00e9 de ne pas accorder d\u2019autorisation de mise sur le march\u00e9 au palovarot\u00e8ne exp\u00e9rimental comme traitement de la fibrodysplasie ossifiante progressive (FOP), maladie osseuse ultra-rare. Il n\u2019existe actuellement dans l\u2019Union europ\u00e9enne pour lutter contre la FOP que des traitements symptomatiques, qui ne diminuent pas la formation de tissu osseux extra-squelettique chez les patients atteints de cette pathologie. Ipsen va solliciter le r\u00e9examen de l\u2019avis du CHMP, sur la base des donn\u00e9es scientifiques issues du programme d\u2019essais cliniques du palovarot\u00e8ne existants.<\/p>\n","protected":false},"excerpt":{"rendered":"","protected":false},"author":5,"template":"","categories":[1233,3563],"tags":[],"class_list":["post-22029","press_release","type-press_release","status-publish","has-post-thumbnail","hentry","category-pressrelease-fr","category-rare-diseases-pressrelease-fr","entry"],"acf":[],"yoast_head":"\nIpsen re\u00e7oit un avis n\u00e9gatif du CHMP sur l\u2019emploi du palovarot\u00e8ne pour traiter les personnes atteintes de fibrodysplasie ossifiante progressive vivant dans l\u2019Union europ\u00e9enne.<\/title>\n<meta name=\"robots\" content=\"index, follow, max-snippet:-1, max-image-preview:large, max-video-preview:-1\" \/>\n<link rel=\"canonical\" href=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/\" \/>\n<meta property=\"og:locale\" content=\"fr_FR\" \/>\n<meta property=\"og:type\" content=\"article\" \/>\n<meta property=\"og:title\" content=\"Ipsen re\u00e7oit un avis n\u00e9gatif du CHMP sur l\u2019emploi du palovarot\u00e8ne pour traiter les personnes atteintes de fibrodysplasie ossifiante progressive vivant dans l\u2019Union europ\u00e9enne.\" \/>\n<meta property=\"og:url\" content=\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/\" \/>\n<meta property=\"og:site_name\" content=\"Global\" \/>\n<meta property=\"article:modified_time\" content=\"2024-07-22T09:11:28+00:00\" \/>\n<meta property=\"og:image\" content=\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28121229\/PR-final-fr-1.jpeg\" \/>\n\t<meta property=\"og:image:width\" content=\"1082\" \/>\n\t<meta property=\"og:image:height\" content=\"620\" \/>\n\t<meta property=\"og:image:type\" content=\"image\/jpeg\" \/>\n<meta name=\"twitter:card\" content=\"summary_large_image\" \/>\n<meta name=\"twitter:site\" content=\"@ipsengroup\" \/>\n<meta name=\"twitter:label1\" content=\"Dur\u00e9e de lecture estim\u00e9e\" \/>\n\t<meta name=\"twitter:data1\" content=\"1 minute\" \/>\n<script type=\"application\/ld+json\" class=\"yoast-schema-graph\">{\"@context\":\"https:\/\/schema.org\",\"@graph\":[{\"@type\":\"NewsArticle\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/#article\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/\"},\"author\":{\"name\":\"\",\"@id\":\"\"},\"headline\":\"Ipsen re\u00e7oit un avis n\u00e9gatif du CHMP sur l\u2019emploi du palovarot\u00e8ne pour traiter les personnes atteintes de fibrodysplasie ossifiante progressive vivant dans l\u2019Union europ\u00e9enne.\",\"datePublished\":\"2023-01-27T08:00:00+00:00\",\"dateModified\":\"2024-07-22T09:11:28+00:00\",\"mainEntityOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/\"},\"wordCount\":156,\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28121229\/PR-final-fr-1.jpeg\",\"articleSection\":[\"Communiqu\u00e9 de presse\",\"Maladies rares\"],\"inLanguage\":\"fr-FR\"},{\"@type\":\"WebPage\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/\",\"url\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/\",\"name\":\"Ipsen re\u00e7oit un avis n\u00e9gatif du CHMP sur l\u2019emploi du palovarot\u00e8ne pour traiter les personnes atteintes de fibrodysplasie ossifiante progressive vivant dans l\u2019Union europ\u00e9enne.\",\"isPartOf\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\"},\"primaryImageOfPage\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/#primaryimage\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/#primaryimage\"},\"thumbnailUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28121229\/PR-final-fr-1.jpeg\",\"datePublished\":\"2023-01-27T08:00:00+00:00\",\"dateModified\":\"2024-07-22T09:11:28+00:00\",\"breadcrumb\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/#breadcrumb\"},\"inLanguage\":\"fr-FR\",\"potentialAction\":[{\"@type\":\"ReadAction\",\"target\":[\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/\"]}]},{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/#primaryimage\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28121229\/PR-final-fr-1.jpeg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28121229\/PR-final-fr-1.jpeg\",\"width\":1082,\"height\":620},{\"@type\":\"BreadcrumbList\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/#breadcrumb\",\"itemListElement\":[{\"@type\":\"ListItem\",\"position\":1,\"name\":\"Home\",\"item\":\"https:\/\/www.ipsen.com\/fr\/home\/\"},{\"@type\":\"ListItem\",\"position\":2,\"name\":\"Ipsen re\u00e7oit un avis n\u00e9gatif du CHMP sur l\u2019emploi du palovarot\u00e8ne pour traiter les personnes atteintes de fibrodysplasie ossifiante progressive vivant dans l\u2019Union europ\u00e9enne.\"}]},{\"@type\":\"WebSite\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#website\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"name\":\"Global\",\"description\":\"\",\"publisher\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\"},\"potentialAction\":[{\"@type\":\"SearchAction\",\"target\":{\"@type\":\"EntryPoint\",\"urlTemplate\":\"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}\"},\"query-input\":\"required name=search_term_string\"}],\"inLanguage\":\"fr-FR\"},{\"@type\":\"Organization\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#organization\",\"name\":\"IPSEN\",\"url\":\"https:\/\/www.ipsen.com\/fr\/\",\"logo\":{\"@type\":\"ImageObject\",\"inLanguage\":\"fr-FR\",\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\",\"url\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"contentUrl\":\"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg\",\"caption\":\"IPSEN\"},\"image\":{\"@id\":\"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/\"},\"sameAs\":[\"https:\/\/www.facebook.com\/Ipsengroup\",\"https:\/\/x.com\/ipsengroup\"]},{\"@type\":\"Person\",\"@id\":\"\"}]}<\/script>\n<!-- \/ Yoast SEO plugin. -->","yoast_head_json":{"title":"Ipsen re\u00e7oit un avis n\u00e9gatif du CHMP sur l\u2019emploi du palovarot\u00e8ne pour traiter les personnes atteintes de fibrodysplasie ossifiante progressive vivant dans l\u2019Union europ\u00e9enne.","robots":{"index":"index","follow":"follow","max-snippet":"max-snippet:-1","max-image-preview":"max-image-preview:large","max-video-preview":"max-video-preview:-1"},"canonical":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/","og_locale":"fr_FR","og_type":"article","og_title":"Ipsen re\u00e7oit un avis n\u00e9gatif du CHMP sur l\u2019emploi du palovarot\u00e8ne pour traiter les personnes atteintes de fibrodysplasie ossifiante progressive vivant dans l\u2019Union europ\u00e9enne.","og_url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/","og_site_name":"Global","article_modified_time":"2024-07-22T09:11:28+00:00","og_image":[{"width":1082,"height":620,"url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28121229\/PR-final-fr-1.jpeg","type":"image\/jpeg"}],"twitter_card":"summary_large_image","twitter_site":"@ipsengroup","twitter_misc":{"Dur\u00e9e de lecture estim\u00e9e":"1 minute"},"schema":{"@context":"https:\/\/schema.org","@graph":[{"@type":"NewsArticle","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/#article","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/"},"author":{"name":"","@id":""},"headline":"Ipsen re\u00e7oit un avis n\u00e9gatif du CHMP sur l\u2019emploi du palovarot\u00e8ne pour traiter les personnes atteintes de fibrodysplasie ossifiante progressive vivant dans l\u2019Union europ\u00e9enne.","datePublished":"2023-01-27T08:00:00+00:00","dateModified":"2024-07-22T09:11:28+00:00","mainEntityOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/"},"wordCount":156,"publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28121229\/PR-final-fr-1.jpeg","articleSection":["Communiqu\u00e9 de presse","Maladies rares"],"inLanguage":"fr-FR"},{"@type":"WebPage","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/","url":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/","name":"Ipsen re\u00e7oit un avis n\u00e9gatif du CHMP sur l\u2019emploi du palovarot\u00e8ne pour traiter les personnes atteintes de fibrodysplasie ossifiante progressive vivant dans l\u2019Union europ\u00e9enne.","isPartOf":{"@id":"https:\/\/www.ipsen.com\/fr\/#website"},"primaryImageOfPage":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/#primaryimage"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/#primaryimage"},"thumbnailUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28121229\/PR-final-fr-1.jpeg","datePublished":"2023-01-27T08:00:00+00:00","dateModified":"2024-07-22T09:11:28+00:00","breadcrumb":{"@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/#breadcrumb"},"inLanguage":"fr-FR","potentialAction":[{"@type":"ReadAction","target":["https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/"]}]},{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/#primaryimage","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28121229\/PR-final-fr-1.jpeg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2022\/08\/28121229\/PR-final-fr-1.jpeg","width":1082,"height":620},{"@type":"BreadcrumbList","@id":"https:\/\/www.ipsen.com\/fr\/press-releases\/ipsen-receives-chmp-negative-opinion-for-palovarotene-as-a-treatment-for-fibrodysplasia-ossificans-progressiva-in-e-u\/#breadcrumb","itemListElement":[{"@type":"ListItem","position":1,"name":"Home","item":"https:\/\/www.ipsen.com\/fr\/home\/"},{"@type":"ListItem","position":2,"name":"Ipsen re\u00e7oit un avis n\u00e9gatif du CHMP sur l\u2019emploi du palovarot\u00e8ne pour traiter les personnes atteintes de fibrodysplasie ossifiante progressive vivant dans l\u2019Union europ\u00e9enne."}]},{"@type":"WebSite","@id":"https:\/\/www.ipsen.com\/fr\/#website","url":"https:\/\/www.ipsen.com\/fr\/","name":"Global","description":"","publisher":{"@id":"https:\/\/www.ipsen.com\/fr\/#organization"},"potentialAction":[{"@type":"SearchAction","target":{"@type":"EntryPoint","urlTemplate":"https:\/\/www.ipsen.com\/fr\/?s={search_term_string}"},"query-input":"required name=search_term_string"}],"inLanguage":"fr-FR"},{"@type":"Organization","@id":"https:\/\/www.ipsen.com\/fr\/#organization","name":"IPSEN","url":"https:\/\/www.ipsen.com\/fr\/","logo":{"@type":"ImageObject","inLanguage":"fr-FR","@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/","url":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","contentUrl":"https:\/\/www.ipsen.com\/websites\/ipsen_com_v2\/wp-content\/uploads\/2023\/12\/07162335\/Latest_Ipsen-logo_168x48.svg","caption":"IPSEN"},"image":{"@id":"https:\/\/www.ipsen.com\/fr\/#\/schema\/logo\/image\/"},"sameAs":["https:\/\/www.facebook.com\/Ipsengroup","https:\/\/x.com\/ipsengroup"]},{"@type":"Person","@id":""}]}},"_links":{"self":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/22029"}],"collection":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release"}],"about":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/types\/press_release"}],"author":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/users\/5"}],"version-history":[{"count":1,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/22029\/revisions"}],"predecessor-version":[{"id":62237,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/press_release\/22029\/revisions\/62237"}],"wp:featuredmedia":[{"embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media\/27874"}],"wp:attachment":[{"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/media?parent=22029"}],"wp:term":[{"taxonomy":"category","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/categories?post=22029"},{"taxonomy":"post_tag","embeddable":true,"href":"https:\/\/www.ipsen.com\/fr\/wp-json\/wp\/v2\/tags?post=22029"}],"curies":[{"name":"wp","href":"https:\/\/api.w.org\/{rel}","templated":true}]}}